drugset / Trial / NCT06210243
C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma
Phase 1
Terminated
2 enrolled
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Shanghai PerHum Therapeutics Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
It is a single-arm, open-label clinical study to assess the safety and efficacy of the C752 CAR-T Cells for patients with CD19+ refractory/relapsed B cell non-Hodgkin lymphoma.
Timeline
- Start
- 2023-12-24
- Primary completion
- 2024-12-24
- Completion
- 2024-12-24
Outcome
Outcome not reported
Stopped: “Due to the PI's determination”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | C752 | Cell therapy | — | — |